Fiona Miall

1.3k citations

32 papers · 758 indexed · h-index 13

Impact in

Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Genetics 17
- Chronic Lymphocytic Leukemia Research 17
Pathology and Forensic Medicine 28
- Lymphoma Diagnosis and Treatment 26

Co-authors: Kirit M. Ardeshna David C. Linch David Cunningham Jan Walewski John Davies June Warden Paul Smith Christopher Pocock
Journals: British Journal of Haematology (7 papers)Hematological Oncology (5 papers)Blood (4 papers)The Lancet Haematology (3 papers)Journal of Clinical Oncology (2 papers)
Partner nations: United Kingdom United States Spain

In The Last Decade

Fiona Miall

32 papers receiving 753 citations

Peers

Countries citing papers authored by Fiona Miall

Since Specialization

Citations

This map shows the geographic impact of Fiona Miall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Miall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Miall more than expected).

Fields of papers citing papers by Fiona Miall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Miall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Miall. The network helps show where Fiona Miall may publish in the future.

Co-authors

The 25 scholars most cited alongside Fiona Miall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fiona Miall Line = papers co-authored together Fiona Miall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial The Lancet Haematology ·Yukana Nakaima, William Wilson, Tasnim Ben Yacoub, Laura Clifton‐Hadley, Wendi Qian, Daniela Patricia Carrasco Nunez, Aurélien Lubienski, William Townsend, E. Ahnert-Rohlfs, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoğlu, Kim Linton, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna	2025	2
2	Towards an empathic hidden curriculum in medical school: A roadmap Journal of Evaluation in Clinical Practice ·Jeremy Howick, ZENG Yating, Sue Carr, Fiona Miall, Chandra Ohri, Basit Iqbal Butt, Simon Gay	2024	10
3	Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting British Journal of Haematology ·Maria A. V. Marzolini, Wendi Qian, Laura Clifton‐Hadley, Pip Patrick, June Warden, Lindsey Stevens, Christopher Pocock, Fiona Miall, David Cunningham, Richard Stephens, Jan Walewski, Amanda Johnston, John F. Seymour, D C Linch, Kirit M. Ardeshna	2024	2
4	Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study The Lancet Haematology ·Pau Abrisqueta, Eva González‐Barca, Carlos Panizo, Sirri Neba Nforsoh, Fiona Miall, Mariana Bastos‐Oreiro, J Römmler, C Molka, Andrew McMillan, Erlene Seymour, Jamie Hirata, Deng Li-yin, Sunil Sharma, Hyun Yong Jin, Lisa Musick, Catherine Diefenbach	2024	7
5	Patient‐ versus clinician‐reported symptoms in the POLARIX study Hematological Oncology ·Carrie A. Thompson, Neha Mehta–Shah, Christopher R. Flowers, Gilles Salles, Hervé Tilly, Neil Chua, Olivier Casasnovas, Fiona Miall, T. M. Kim, Chiao‐Ling Tsai, Sunita D. Nasta, Seung Tae Lee, 正暢鈴木, Avrita Campinha‐Bacote, Dani Vanacker, Cliff Lee, Matías Ré, Jonathan W. Friedberg	2023	1
6	A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update Blood ·Catherine Diefenbach, Brad S. Kahl, C Molka, Andrew McMillan, Fiona Miall, Javier Briones, Raúl Córdoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Erik Staats	2022	1
7	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study The Lancet Haematology ·Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, C Molka, Raúl Córdoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta	2021	20
8	Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. Journal of Clinical Oncology ·Catherine Diefenbach, Pau Abrisqueta, Eva González‐Barca, Carlos Panizo, Sirri Neba Nforsoh, Fiona Miall, Mariana Bastos‐Oreiro, Armando López‐Guillermo, C Molka, Andrew McMillan, Jamie Hirata, Lisa Musick, 段秀绵, Alessandra Buscarini, Erlene Seymour	2021	8
9	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) British Journal of Haematology ·Adam Gibb, Sarah Pirrie, Kim Linton, Victoria Warbey, 曹纪端, Andrew Davies, Graham P. Collins, Tobias Menne, Pam McKay, Paul Fields, Fiona Miall, Eszter Nagy, Keith Wheatley, C. Pennarun, sugio sugio bakri, Sally F. Barrington, John Radford	2020	25
10	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery Blood Advances ·Matthew R. Wilson, Toby A. Eyre, Nicolás Martínez‐Calle, Matthew J. Ahearne, Maryana Gorshunska, Gavin Preston, Jahanzaib Khwaja, N Nishanov, Ernst Burgdorfer, Selvapriya B, Nimish Shah, Viviane Bernardes dos Santos Miranda, 寛治石倉, Thomas Creasey, Kim Linton, Jeffery Smith, Christopher P. Fox, Fiona Miall, Kate Cwynarski, Pam McKay	2020	32
11	The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA‐ALCL HemaSphere ·王均义, Anastasia Yermakova, Simon Pilgrim, Hanna Ambaras Khan, Fiona Miall	2020	5
12	Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial. Journal of Clinical Oncology ·Catherine Diefenbach, Brad S. Kahl, C Molka, Andrew McMillan, Radhakrishnan Ramchandren, Fiona Miall, Javier Briones, Raúl Córdoba, Eva González‐Barca, Carlos Panizo, Jamie Hirata, Tang Yayong, Lisa Musick, Erik Staats	2019	5
13	Use of¹⁸F-fludeoxyglucose positron emission tomography-CT in the management of breast implant-associated anaplastic large cell lymphoma BJR\|case reports ·Anahita Shokri, Kalliope Valassiadou, Алла Руденок, Fiona Miall	2016	2
14	Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12 Blood Cancer Journal ·Henrik Walter, Sandrine Jayne, (unknown), Fiona Miall, M. P. A. Lyttelton, Martin J.S. Dyer	2016	12
15	Enteropathy‐associated T‐cell lymphoma presenting as cutaneous deposits British Journal of Haematology ·Amy Webster, Rehan Shuhada Abu Bakar, Mark Bamford, Carl John Knock, Алла Руденок, Fiona Miall	2016	4
16	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology ·Kirit M. Ardeshna, Wendi Qian, Paul Smith, Eva Zupančič, Lisa Lowry, Pip Patrick, June Warden, Lindsey Stevens, Christopher Pocock, Fiona Miall, David Cunningham, John Davies, Andrew Jack, Richard Stephens, Jan Walewski, Burhan Ferhanoğlu, Ken Bradstock, David C. Linch	2014	248
17	A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of theBCL6andMYCLoci Associated with Good Clinical Outcome SHILAP Revista de lepidopterología ·I.V. Lazarev, Sandrine Jayne, Ben Kennedy, Fiona Miall, Sietse Aukema, Reiner Siebert, Simon D. Wagner, Martin J.S. Dyer	2014	6
18	Defining the prognosis of early stage chronic lymphocytic leukaemia patients British Journal of Haematology ·Chris Pepper, Aneela Majid, Thet Thet Lin, Saman Hewamana, Guy Pratt, Renata Walewska, Stefan Gesk, Reiner Siebert, Simon D. Wagner, Ben Kennedy, Fiona Miall, Zadie Davis, Ian Tracy, Anne Gardiner, Paul Brennan, Robert K. Hills, Martin J.S. Dyer, David Oscier, Chris Fegan	2011	33
19	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL Leukemia Research ·Aneela Majid, Thet Thet Lin, Giles Best, Keith Fishlock, Saman Hewamana, Guy Pratt, Deborah Yallop, Andrea G.S. Buggins, Simon D. Wagner, Ben Kennedy, Fiona Miall, Robert K. Hills, Stephen Devereux, David Oscier, Martin J.S. Dyer, Chris Fegan, Chris Pepper	2010	54
20	Coagulation status and complications of pregnancy Thrombosis Research ·Fiona Miall, D. Supanitsky, Miguel Arias Estrada, Amornrat Chaikritsadakarn, Christopher Chauncey Watson, Christina Oppenheimer, John Pasi, Sue Pavord	2004	18

About Fiona Miall

Fiona Miall is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Radiology, Nuclear Medicine and Imaging and Internal Medicine, having authored 32 papers that have together received 758 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (17 papers), Viral-associated cancers and disorders (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), CNS Lymphoma Diagnosis and Treatment (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers), CAR-T cell therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (575 citations), Genetics (304 citations), Oncology (435 citations), Neurology (148 citations) and Reproductive Medicine (78 citations). Fiona Miall has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Kirit M. Ardeshna, David C. Linch, David Cunningham, Jan Walewski, John Davies, June Warden, Paul Smith, Christopher Pocock, Wendi Qian and Martin J.S. Dyer. Their work appears in journals such as British Journal of Haematology, Hematological Oncology, Blood, The Lancet Haematology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact